The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy.
The NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years.
This study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine / Allergology
Eligibility criteria
Qualifiers
Age >18 and ≤60 years
Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and/of immunocap for the specific IgEs.
Patients who start with AIT treatment
The patient must be motivated and willing to come to all visits
Disqualifiers
Uncontrolled asthma
Conditions affecting the functioning of the immune system (eg: immune deficiencies, malignancies, autoimmune diseases)
Use of β-blockers, immunosuppressants or ACE inhibitors
Hypersensitivity to aluminum hydroxide and/or hypersensitivity to any of the excipients in AIT
Trial design
Treatments tested in this trial
- AIT
- NAPT
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
AZ Sint-Jan AV
Collaborator
Source ClinicalTrials.gov